Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Incyte Corporation
Xencor, Inc.
Incyte Corporation
AbbVie
AbbVie
Incyte Corporation
Incyte Corporation
Abramson Cancer Center at Penn Medicine
Swiss Cancer Institute
INSYS Therapeutics Inc
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)